logo-loader

Scancell chief hints at future Nasdaq listing

Published: 03:18 15 Oct 2015 EDT

Richard Goodfellow, chief executive of Scancell (LON:SCLP), says the immuno-oncology specialist could explore the option of a NASDAQ listing once it has built up its North American profile.

The CEO was speaking to Proactive following the announcement of two new appointments - Dr John Chiplin, who will join the board as a non-executive director, and Dr Peter Brown, who is to be an advisor to the drug developer.

The former brings with him a wealth of industry experience, having been instrumental in the NASDAQ listing of Australia-quoted Benitec Biopharma.

Scancell’s first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials.

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023